News from KI

Newsfeed delivered by KI.se

News from KI

Christer Betsholtz awarded the 2018 Louis-Jeantet Prize for Medicine

Tuesday January 23rd, 2018 05:05:48 PM
Kommunikationsavdelningen

The 2018 Louis-Jeantet Prize for Medicine is awarded to Christer Betsholtz, Director of the Integrated Cardio Metabolic Centre at Karolinska Institutet, and Professor at Uppsala University.

Christer Betsholtz is awarded the prize of SEK 5.8 million for his seminal discoveries in vascular biology, in particular the characterisation of specialised cells – pericytes – and their role in vascular development and permeability.

The 2018 Louis-Jeantet Foundation grants the sum of CHF 700,000 for each of the two prizes, of which CHF 625,000 is for the continuation of the prize-winner's research and CHF 75,000 for their personal use.

 

 

News category: 
News type: 


Silver Medal 2017 to Lars-Olof Wahlund and Eva Mattsson

Tuesday January 23rd, 2018 10:57:57 AM
Kommunikationsavdelningen

Karolinska Institutet’s Silver Medal for 2017 is awarded to Lars-Olof Wahlund and Eva Mattsson. The medals are awarded to those who have made a special contribution to supporting KI’s activities.
The vice-chancellor, in consultation with the pro-vice-chancellor, university director and the deans of research, doctoral education and higher education, awards Karolinska Institutet’s various medals based on recommendations from the Medals Committee.

Extracts from the Committee’s reasons for awarding the silver medals:

Lars-Olof Wahlund, senior professor in geriatrics, receives the medal for the major impact his work as a teacher, clinician and researcher has had on KI’s leading position in the field of dementia research. His scientific productivity is high, with in the region of 450 publications, and he is a leader within KI in the field of magnetic resonance-based research into dementia disorders.

 

Eva Mattsson, professor emerita in physiotherapy, receives the medal for her distinguished contribution to doctoral and higher education and research at Karolinska Institutet. Throughout the course of her professional life, she has been an eminent researcher who has influenced clinical praxis, as well as a forceful proponent of quality in first cycle, second cycle and doctoral education, not only in KI’s physiotherapy programme, but also within KI as a whole.

The medals are being presented in conjunction with the “För nit och redlighet i rikets tjänst”, NOR, awarding ceremony, on 15 February.

News category: 
News type: 


Reduced dental anxiety among children with internet-based CBT

Tuesday January 23rd, 2018 10:35:27 AM
Kommunikationsavdelningen

Researchers at Karolinska Institutet have developed an accessible therapy for children and adolescents suffering from dental phobia. The study, published in the Journal of Medical Internet Research, shows that guided internet-based CBT is highly effective in reducing anxiety and increasing the ability to deal with dental treatment. One year later, half of the children were completely free of their phobia.

Dental anxiety often begins in childhood or adolescence, and can develop into a phobia with avoidance, strong negative feelings and thoughts aimed at dental care. Avoidance of dental care often leads to poor oral health, untreated caries or other dental problems.

Cognitive behavioural therapy (CBT) is an effective treatment for most forms of specific phobia. However, with regard to children and adolescents with dental phobia, there are organisational, financial and geographic obstacles to providing such therapy. Researchers in this study have therefore developed an internet-based CBT treatment that they have tested in an open, uncontrolled study of 18 patients between the ages of 8 and 15.

Treatment continued for 12 weeks

During the study, participants used an internet platform to obtain weekly online guidance from a psychologist via a chat system. Treatment continued for 12 weeks and included texts, animations and dental-related video clips. The treatment also included an exercise package with a dental mirror, probe, local anaesthetic and cannula delivered to the home of the child/parent(s) with detailed instructions for the exercises. Through therapy and guidance from the psychologist, the home-based exercises were linked to real exposure and training visits to dental clinics around Sweden.

The results show a statistically and clinically-significant increase in the children’s ability to manage dental treatment. The internet-based CBT also increased children’s and parents’ self-efficacy, led to fewer negative thoughts and reduced anxiety aimed at dental treatment. At a one-year follow up, 53 per cent of the children were completely free of their dental phobia.

Surprisingly strong effects

“Even though we expected positive effects from the therapy, it was still surprising to see the scope of improvement and the strong effects of the therapy among the patients, given that they did not have a single physical meeting with the psychologist,” explains Shervin Shahnavaz at Karolinska Institutet’s Department of Dental Medicine who is the researcher behind the development of the therapy.

The researchers now hope to be able to repeat the results in an ongoing randomised controlled trial.

“Internet-based CBT for dental phobia in children and adolescents may be an efficient form of therapy with the potential to increase access to effective treatment,” says Dr Shahnavaz.

The study is the result of a collaboration with Stockholm County Council’s unit for internet psychiatry. The research project was supported with grants from SOF; board of dental research at Karolinska Institutet and Stockholm County Council and the Mayflower Charity Foundation for children.

Publication

Shahnavaz S, Hedman-Lagerlöf E, Hasselblad T, Reuterskiöld L, Kaldo V, Dahllöf G
”Internet-Based Cognitive Behavioral Therapy for Children and Adolescents With Dental Anxiety: Open Trial”
J Med Internet Res 2018;20(1):e12, online 22 January 2018, doi:10.2196/jmir.7803

Image: 
Tandvårdsrädsla börjar ofta i barndomen eller tonåren. Foto: iStockDental anxiety often begins in childhood or adolescence. Photo: iStock 
News category: 
News type: 


Current calls, week 4, 2018

Monday January 22nd, 2018 03:21:17 PM
Kia Olsson

Tips from KI Grants Office about current calls

Swedish and Nordic grants

Interdisciplinary synergy programme – Novo Nordisk Foundation

This aims to stimulate an interdisciplinary culture of research that spans across scientific disciplines and techniques, pursue creative and novel, high-risk and high-gain research ideas, as well as strengthen and internationalise Danish research. Grants are worth DKK 5 million per year for up to three years.

Closing date: 6 Feb 2018

Interdisciplinary synergy programme – Novo Nordisk Foundation

JSPS Summer Program – Swedish Foundation for International Cooperation in Research and Higher Education (STINT)

This enables investigators to pursue collaborative research at Japanese universities and research institutes, thereby allowing them to advance their own research while promoting scientific progress in both Japan and their respective countries.

Closing date: 8 Feb 2018

JSPS Summer Program – Swedish Foundation for International Cooperation in Research and Higher Education (STINT)

Stora forskningsanslag – Swedish Heart-Lung Foundation

Detta syftar till att skapa förutsättningar för ett avgörande forskningsgenombrott inom hjärt-och lungforskning. Anslag uppgår till SEK 5 miljoner per år under en treårsperiod.

Closing date: 14 Feb 2018

Stora forskningsanslag – Swedish Heart-Lung Foundation 

Call for International Collaboration within Antimicrobial Resistance – Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)

In 2017 the WHO published the Global priority pathogen list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics (PPL). The JPIAMR 6th joint call is a direct response to the list. The aim is to discover new targets, compounds, or new tools with the potential to help controlling infections by drug-resistant bacteria identified by the WHO as priority pathogens.

Closing date: 7 March 2018

Call for International Collaboration within Antimicrobial Resistance – Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) 

Forskningsanslag – Aroseniusfonden

Aroseniusfonden inbjuder ansökningar om forskningsanslag. Dessa stöder medicinsk forskning rörande hemofili, von Willebrands sjukdom, andra blödningsrubbningar och genterapi.Behöriga att söka är forskare eller forskargrupper. Anslaget kan användas till driftkostnader eller lön.

Closing date: 8 March2018

Forskningsanslag – Aroseniusfonden 

Symposia – Novo Nordisk Foundation

The Novo Nordisk Foundation invites applications for funding for symposia. These provide support for the organisation of symposia which offer leading as well as younger researchers with opportunities to present and discuss the newest research within their fields. Up to two one-day symposia are supported with up to DKK 320,000 each.

Closing date: 13 March 2018

Symposia – Novo Nordisk Foundation

Nordic workshops – Joint Committee of the Nordic Research Councils for Humanities and Social Sciences

These promote research collaboration and development of new research areas and programmes within the humanities and social sciences in the Nordic countries through a series of workshops. The total budget of the call is approximately SEK 13.5 million and grants range from SEK 300,000 to SEK 450,000.

Closing date: 20 March 2018

Nordic workshops – Joint Committee of the Nordic Research Councils for Humanities and Social Sciences 

Lisa och Johan Grönbergs Stiftelse

Lisa och Johan Grönbergs Stiftelse avser att dela ut ett antal anslag om max 100 000 kronor per anslag till disputerade forskare. Årets ämne är ”endokrina tumörer och sjukdomar, ej diabetes”.
Ansökningsperioden är öppen från den 1 mars klockan 00.01 t o m 31 mars klockan 23.59.

Sista ansökningsdag: 31 mars
Ansökan görs elektroniskt. Information och anvisningar.

European grants

Grants4Targets – Bayer

Bayer invites applications for its Grants4Targets – novel targets for drug development initiative. The initiative aims to encourage research on novel targets in the fields of oncology, gynaecology, heart and vascular diseases, specialty lung diseases and hemostatic and acute organ disorders. The following different types of grants are available:

•support grants worth between €5,000 and €10,000 to advance research on targets that are at a very early stage of discovery;

•focus grants worth between €10,000 and €125,000 for more mature ideas, such as addressing specific aspects of a target as a first step towards transferring it to the drug discovery process.

Closing date: 31 March 2018

Grants4Targets – Bayer

Practical courses - European Molecular Biology Organisation

The European Molecular Biology Organisation invites applications for its practical courses. Funding supports the organisation of courses to promote the transfer of new methods and emerging techniques in life science-related areas, and to enable participating students to implement novel techniques in their home laboratories

Closing date: 1 March 2018

Practical courses - European Molecular Biology Organisation

Workshops - European Molecular Biology Organisation, EUR

The European Molecular Biology Organisation invites applications for its grants to support workshops. These enable the organisation of workshops that cover different and evolving aspects of life-science related subject areas and bring scientists together to present their findings. Workshops should last between two and a half and five days, and attract between 80 and 450 participants.

Closing date: 1 March 2018

Workshops - European Molecular Biology Organisation, EUR 

Training course and workshop awards - European Society for Paediatric Infectious Diseases

The European Society for Paediatric Infectious Diseases invites applications for its training course and workshop awards. These support the organisation of training courses and workshops in paediatric infectious diseases. Events may be directed at clinical trainees, continuing medical education for career grade doctors, or both.

Closing date: 1 March 2018

Training course and workshop awards - European Society for Paediatric Infectious Diseases 

Advanced courses grants - Federation of European Biochemical Societies (FEBS)

The Federation of European Biochemical Societies invites proposals for its Advanced courses grants, for events to run in 2019. These enable individuals and groups to organise lecture courses, workshops and practical courses covering relevant and timely scientific topics related to biochemistry, biophysics, molecular biology, cell biology and developmental biology, and usually with an educational emphasis

Closing date: 1st March 2018

Advanced courses grants - Federation of European Biochemical Societies (FEBS) 

US grants

Federal Funding agencies

Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01): NIH

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status.

A distinguishing feature of each application will be formation of an academic-industrial partnership, which is a strategic alliance of investigators in academic, industrial, and any other entities who work together as partners to identify and translate a technological solution or mitigation of a cancer-related problem.

The goals for proposed technologies are imaging applications in clinical trials, clinical research, non-clinical research, and/or patient care. Among other possibilities, they may include pre-clinical imaging investigations or investigations that combine patient specimens and pre-clinical methods, or optimizations of methods across different commercial platforms, sites, or time.

Closing dates: Feb 5, June 5, and Oct 5, 2018, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-18-009

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01): NIH

This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status.

Closing dates: First due date is March 8, 2018. Thereafter Standard dates apply, by 5:00 PM local time of applicant organization until Jan 8, 2021.

Funding Opportunity Announcement (FOA): PAR-18-530

Diet and Physical Activity Assessment Methodology (R21): NIH

This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors.    

Closing dates:  June 16, 2018 (new applications) and Sept 7, 2018 (AIDS applications) by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-18-112 (R21)

Hearing Health Care for Adults: Improving Access and Affordability (R01, R21): NIH

This FOA encourages exploratory and developmental research applications for research on hearing health care in adults in support of improving access and affordability.  Further research is needed to strengthen the evidence base with a goal of delivering better health care outcomes in adults.

Closing date: Standard dates apply, by 5:00 PM local time of applicant organization until Nov 6, 2020.

Funding Opportunity Announcement (FOA): PA-18-438 (R01); PA-18-382 (R21)

Underactive Bladder and Detrusor Activity in Aging (R01, R03, R21): NIH

This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons.

Closing date: Standard dates apply, by 5:00 PM local time of applicant organization until May 8, 2021.

Funding Opportunity Announcement (FOA): PA-18-570 (R01); PA-18-574 (R03); PA-18-572 (R21)

Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01, R21): NIH

This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and Alzheimer's disease-related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of AD/ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in AD/ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and AD/ADRD.

Closing dates: March 29, 2018; June 8, 2018; Feb 8, 2019; June 7, 2019; Feb 7, 2020; and June 8, 2020, by 5:00 PM local time of applicant organization (R01); March 29, 2018; June 20, 2018; Feb 20, 2019; June 20, 2019; Feb 20, 2020; and June 22, 2020, by 5:00 PM local time of applicant organization (R21).

Funding Opportunity Announcement (FOA): PAR-18-581 (R01); PAR-18-582 (R21).

Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional)

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio. The proposed research should: (1) test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking; and/or (2) develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research.

Closing dates: Aug 20, 2018; Dec 20, 2018; Aug 20, 2019; Dec 20, 2019; Aug 20, 2020; and Dec 18, 2020, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-18-437

Foundations

Applied research grants: Organization for Autism Research

 The Organization for Autism Research (OAR) seeks proposals for its 2018 Applied Research Competition. Through this competition, OAR intends to promote evidence-based practices delivered from research in the following areas:

The analysis, evaluation, or comparison of current models of assessment, intervention, or systems of service delivery, including policy analysis
Applied aspects of educational, behavioral, or social/communicative intervention
Effective intervention across the lifespan for individuals considered to be severely impacted by autism
Adult issues such as continuing education, employment, residential supports, sexuality instruction, quality-of-life determinants, and “later intervention”
Issues related to family support, social and community integration, assessment and intervention with challenging behavior, and the use of technology in support of learners with ASD

Closing dates: March 26, 2018, 11:59 PM ET (Preproposals); August 6, 2018, 11:59 PM ET (Full proposals by invitation only).

Applied research grants: Organization for Autism Research 

New Investigator, Small exploratory, Standard grants: Scoliosis Research Society

New investigator research grants are meant to stimulate young members into a career of investigation in spinal deformity. The small exploratory research grant is intended to be for “high-risk, high reward” projects. Qualitatively, the standard for reviewers of a grant in this category “Standard Grant”, is that the successfully completed project would be of a quality of a well-received podium presentation at the SRS Annual Meeting. The Society expects that these grants will lay the foundation for a sustained avenue of investigation and allow the investigator(s) to seek larger grants from sources such as the NIH.

New Investigator, Small exploratory, Standard grants: Scoliosis Research Society 

News category: 
News type: 
Organisational unit: 


Two KI researchers accepted Wallenberg Clinical Fellows

Monday January 22nd, 2018 12:57:02 PM
Kommunikationsavdelningen

Researchers Petter Brodin and Carl Sellgren Majkowitz at Karolinska Institutet have been accepted into the Wallenberg Clinical Fellows research programme, meaning a three-year appropriation financed by the Marianne and Marcus Wallenberg Foundation.

Petter Brodin is an assistant professor at Karolinska Institutet’s Department of Medicine, Solna and Science for Life Laboratory, as well as a resident in paediatrics at the Karolinska University Hospital. His research deals with how the immune systems of infants are formed by environmental factors such as bacteria, viruses and nutritional components. Together with his research group, he has developed a completely unique experimental method based on a new sampling method.

Carl Sellgren Majkowitz is a senior researcher at KI’s Department of Physiology and Pharmacology, as well as an attending physician at Karolinska University Hospital. Carl Sellgren Majkowitz and his research group are attempting to develop a new treatment for those suffering from schizophrenia and bipolar disorder that will cause fewer side effects than existing treatments.

The purpose of the Wallenberg Clinical Fellows research programme is to stimulate clinical research among Swedish physicians and to identify the leading researchers of tomorrow in a clinical environment. The programme is primarily aimed at younger doctors. The initiative is the work of the Marianne and Marcus Wallenberg Foundation with scientific support from the Royal Swedish Academy of Sciences.

News category: 
News type: 


CLINTEC’s file server unavailable Monday, January 22 after 5 pm

Monday January 22nd, 2018 08:32:54 AM
Tabea Kemna

The file server at the Department of Clinical Science, Intervention and Technology will not be available today, January 22, from 5 pm until tomorrow, January 23, 8 am, due to a reorganization of the server.

During this period you won’t be able to access files stored on the server.

In order to get access to the new file server you need to be connected to a KI-net with cable (not Wi-Fi) after the update.

In case you have any questions, please contact the IT support at it-support@ki.se.

News type: 


GDPR: project status and ongoing work

Friday January 19th, 2018 03:27:03 PM
Viktoria Olausson

We continue the work after the winter break and current tasks are:

• Collection and updating of existing guidelines and rules regarding the handling of personal data in order to prepare instructions due in the beginning of April
• Review the current data processing agreements to make recommendations on how to handle them, and to develop guidelines for establishing new data processing agreements
• Review current templates for consent of personal data handling in order to update these to GDPR
• Update the information classification modelmodel before the work of information classification primarily in recommended storage sites, secondly in common systems for KI and thirdly in local systems at the institutions

News type: 


Johanna Snäll, CIM, defended her thesis on January 18th

Friday January 19th, 2018 01:27:44 PM
Emma Karlsson

Congratulations to Johanna Snäll, Center for Infectious Medicine, who defended her thesis on January 18th. 

Title on thesis: Phagocytic cells and Streptococcus pyogenes in invasive infections : an inflammatory relationship

Main supervisor was Professor Anna Norrby-Teglund, Center for Infectious Medicine

Co-supervisor was Linda Jervelius, Center for Infectious Medicine

Opponent was Rachel Mc Loughlin, Trinity College Dublin 

News type: 
Organisational unit: 


Demonstration for Ahmadreza Djalali

Friday January 19th, 2018 09:28:06 AM
Kommunikationsavdelningen

On Thursday, Amnesty International’s Swedish section and Karolinska Institutet held a joint demonstration in support of the physician and researcher Ahmadreza Djalali, currently facing a death sentence in Iran.

The demonstration in support of Ahmadreza Djalali, who has been imprisoned in Iran since April 2016, was held at Campus Solna. Ahmadreza Djalali’s wife, Vida Mehrannia, also attended the demonstration.

Ahmadreza Djalali was sentenced to death in October 2017 for alleged espionage on behalf of the Israeli government. Although Djalali is an Iranian citizen, he has a permanent residence permit in Sweden and was previously a researcher in disaster medicine at Karolinska Institutet, where he also defended his thesis in 2012.

Amnesty International considers Ahmadreza Djalali to be a prisoner of conscience who has been arbitrarily imprisoned and is demanding that the Iranian authorities quash the sentence and release him.

Ole Petter Ottersen, Vice-Chancellor of Karolinska Institutet, participated in the demonstration. Among other things, he spoke of the human right to a free and just trial, the fact that the death penalty conflicts with human dignity, human rights and international standards, as well as every value for which Karolinska Institutet stands.

“As academics, we have a great responsibility towards the fight to abolish the death penalty and to maintain academic freedom, so let us make ourselves heard,” declared Ole Petter Ottersen.

In 2014, during his time as vice-chancellor of the University of Oslo, Ole Petter Ottersen was instrumental in starting the Universities Against the Death Penalty network.

During the demonstration, Anna Lindenfors, Director at Amnesty International Sweden, explained that, as the Supreme Court of Iran confirmed the death penalty in December, the only remaining possibility is a judicial review of the entire case that may change the verdict.

“This is a very serious situation. Ahmadreza Djalali must be immediately and unconditionally released so that he can be reunited with his wife and children in Sweden and continue his research,” said Anna Lindenfors.

Lisa Kurland, previously Djalali’s supervisor and professor in emergency care at Örebro University, contributed a more personal picture of her friend and colleague.

“Ahmadreza Djalali travelled to Iran, the land of his birth and a country he loved, in order to pass on his knowledge. It pains me that he is imprisoned, and it is beyond comprehension that he is sentenced to death,” she said.

 

Text: Helena Mayer

Image: 
Ole Petter Pettersen under manifestationen. Foto: Andreas AnderssonOle Petter Pettersen during the demonstration. Photo: Andreas Andersson 
News category: 
News type: 


Michael Landreh, David Lane, Sonia Lain, Marcus Ladds et al publish in Cell Chemical Biology

Friday January 19th, 2018 08:28:52 AM
John Sennett

In a study published in Cell Chemical Biology this week, researchers from MTC (Michael Landreh, David Lane, Sonia Lain, Marcus Ladds et al), KTH, Uppsala University, and the University of Oxford, used a new strategy to find out how anticancer drugs bind to the membrane protein dehydroorotate dehydrogenase (DHODH), a new cancer target.

The groups of Sir David Lane and Sonia Lain at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet used native mass spectometry, a technique where a protein is gently removed from its normal environment and accelerated into a vacuum chamber. By measuring the time it takes for the protein to fly through the chamber, it is possible to determine its exact weight, which can, in turn, indicate whether the protein has bonded to another molecule and if so, what kind. The researchers used this highly accurate ”molecule scale” to see how drugs and lipids, the building blocks of the cell membrane, bind to DHODH.

Read the full news story here: Flying membrane protein aids cancer drug design

News type: 







Feed aggregation powered by Syndicate Press.
Processed request in 0.11792 seconds.

Read more posts…